Gross Proceeds of $11.3 Million at Initial Closing

首次交割时总收益为1,130万美元

Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

由NantWorks创始人Patrick Soon-Shiong博士主导的交易

PRINCETON, N.J., Sept. 14, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ('PDS Biotech' or the 'Company'), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced the initial closing (the “Initial Closing”) of the Company’s Private Investment in Public Equity (“PIPE”) transaction.

新泽西州普林斯顿，2026年9月14日（环球电讯社）——专注于开发癌症靶向免疫疗法的临床阶段生物技术公司PDS Biotechnology Corporation（纳斯达克股票代码：PDSB）（“PDS Biotech”或“公司”）今日宣布，其私募股权投资于公开股权（“PIPE”）交易已完成初步交割（“初步交割”）。

The round was led by Nant Capital, LLC (“Nant”) with additional participation by current investors. The PIPE also consists of a contingent milestone closing (the “Milestone Closing”) as described below..

本轮融资由 Nant Capital, LLC（“Nant”）领投，现有投资者也参与了跟投。该私募股权投资还包含一项或有里程碑交割（“里程碑交割”），具体如下所述。

At the Initial Closing, the Company sold (i) shares of the Company’s common stock (the “Private Placement Shares”) or, at the election of an investor, pre-funded warrants in lieu of such shares (“Pre-Funded Warrants”), and (ii) accompanying common stock purchase warrants (“Common Warrants”). Each unit consisting of one Private Placement Share and a Common Warrant to purchase one-half of one Private Placement Share (“Common Warrants”) was issued for $0.2825 (the “Share Unit Purchase Price”), and each unit consisting of one Pre-Funded Warrant to purchase one share of Common Stock and a Common Warrant to purchase one-half of one share of Common Stock was issued for $0.28217 (the “Pre-Funded Unit Purchase Price”).

在初始交割时，公司出售了（i）公司普通股股份（“私募配售股份”），或根据投资者选择，以预付认股权证代替该等股份（“预付认股权证”），以及（ii）随附的普通股购买认股权证（“普通认股权证”）。每个由一股私募配售股份和一份购买半股私募配售股份的普通认股权证组成的单位，发行价格为0.2825美元（“股份单位购买价格”）；每个由一份购买一股普通股的预付认股权证和一份购买半股普通股的普通认股权证组成的单位，发行价格为0.28217美元（“预付单位购买价格”）。

The aggregate gross proceeds and the aggregate number of Private Placement Shares, Pre-Funded Warrants and Common Warrants issued as part of the Initial Closing were approximately $11.3 million, and 16,502,870, 23,498,156 and 20,000,514, respectively..

作为初始交割的一部分，总募集总额以及发行的私募股份、预融资权证和普通权证的数量分别约为1,130万美元，以及16,502,870股、23,498,156份和20,000,514份。

The Company intends to use the net proceeds from the private placement to repay outstanding indebtedness and for working capital and general corporate purposes, including the continued development of its clinical programs, research and development, and general and administrative expenses. The Company also expects that the PIPE will advance PDS0301 (also referred to as PDS01ADC or NHS-IL12) into late-stage clinical development, based on recent promising interim Phase 2 clinical trial data in microsatellite stable (MSS) and mismatch repair-proficient (pMMR) metastatic colorectal cancer (mCRC), types of colorectal cancer that have not responded well to treatment with immunotherapy. Patients with MSS and pMMR mCRC with liver metastases historically have dire treatment outcomes, with median overall survival of less than 12 months.*  In a National Cancer Institute (NCI) led Phase 2 trial, the addition of PDS0301 to standard of care therapy in 22 patients was well tolerated, and demonstrated deep and long-lasting tumor shrinkage and survival, with 80% of patients surviving for at least 24 months..

本公司拟将私募发行的净收益用于偿还未偿债务，以及满足营运资金和一般公司用途，包括持续推进其临床项目、研发活动以及一般和管理费用。本公司还预计，基于近期在微卫星稳定（MSS）和错配修复功能完整（pMMR）转移性结直肠癌（mCRC）患者中取得的令人鼓舞的二期临床试验中期数据，PIPE投资将推动PDS0301（亦称PDS01ADC或NHS-IL12）进入后期临床开发阶段。MSS和pMMR型mCRC是对免疫疗法反应不佳的结直肠癌亚型。历史上，伴有肝转移的MSS和pMMR mCRC患者的治疗预后极差，中位总生存期不足12个月*。在一项由美国国家癌症研究所（NCI）主导的二期临床试验中，对22名患者在标准治疗基础上加用PDS0301，该方案耐受性良好，并显示出显著且持久的肿瘤缩小效果及生存获益，80%的患者生存期至少达到24个月。

At the Milestone Closing, which will be triggered by the Company’s submission of a registrational Phase 3 clinical trial protocol for PDS0301 designed in collaboration with Nant to the FDA, Nant and AB Group Ltd. will be obligated to purchase and the Company will be obligated to issue to each of Nant and AB Group Ltd., shares of common stock or Pre-Funded Warrants in lieu thereof for an aggregate purchase price of $10,000,000 and $1,000,000, respectively, subject to the satisfaction or waiver of the applicable closing conditions.

在里程碑式交割时（该交割将由公司向美国食品药品监督管理局（FDA）提交与Nant合作设计的PDS0301注册性III期临床试验方案触发），Nant和AB集团有限公司将有义务购买，公司亦有义务向Nant和AB集团有限公司分别发行普通股或替代的预融资认股权证，总购买价格分别为10,000,000美元和1,000,000美元，前提是满足或豁免适用的交割条件。

The number of securities purchased by any investor will be subject to a 19.9% beneficial ownership limitation..

任何投资者购买的证券数量均受19.9%的受益所有权上限限制。

In addition to the PIPE transaction, and for additional consideration, the Company granted  NantWorks, LLC, an affiliate of Nant, a one-year exclusive right to negotiate an exclusive license to PDS0101, the Company’s novel investigational human papilloma virus targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers.

除PIPE交易外，作为额外对价，公司授予Nant的关联方NantWorks, LLC一项为期一年的独家谈判权，以就PDS0101的独家许可进行谈判。PDS0101是公司的一种新型 investigational 人乳头瘤病毒（HPV）靶向免疫疗法，能够激发强效的靶向T细胞攻击，对抗HPV阳性癌症。

The option has a term of one year..

该期权的期限为一年。

Effective as of the Initial Closing, Dr. Soon-Shiong and Mr. James Banaag, who currently serves the as chief financial officer of NantBio, Inc., will join the Company’s board of directors.

自首次交割生效之日起，Soon-Shiong 博士和目前担任 NantBio, Inc. 首席财务官的 James Banaag 先生将加入公司董事会。

Dr. Soon-Shiong commented, “PDS Biotechnology is developing promising novel cancer vaccines and immunocytokines that have demonstrated the potential to harness the power of the immune system to transform cancer care.  This is an area of significant interest for me, and I am pleased to join the board of directors and to be able to contribute towards the advancement of these therapies that are aimed at addressing difficult-to-treat cancers.” .

黄馨祥博士评论道：“PDS Biotechnology 正在开发前景广阔的新型癌症疫苗和免疫细胞因子，这些产品已展现出利用免疫系统力量、变革癌症治疗的潜力。这一领域令我高度关注，我很高兴加入董事会，并为推动这些旨在攻克难治性癌症的疗法的发展贡献力量。”

Dr. Frank Bedu-Addo, founder and CEO of PDS Biotechnology stated, “We believe that the ongoing clinical trials of our IL-12 immunocytokine PDS0301 at the NCI strongly suggest that PDS0301 has the potential to advance the treatment of solid tumors with immunotherapy.  We also believe that clinical trials of our cancer vaccine platform demonstrate the potential to advance the field of targeted T cell immunotherapy.

PDS Biotechnology 创始人兼首席执行官 Frank Bedu-Addo 博士表示：“我们相信，我们在美国国家癌症研究所（NCI）开展的 IL-12 免疫细胞因子 PDS0301 的正在进行中的临床试验强烈表明，PDS0301 具有推动实体瘤免疫治疗发展的潜力。我们还认为，我们癌症疫苗平台的临床试验展示了推动靶向 T 细胞免疫治疗领域发展的潜力。”

We are extremely pleased that Dr. Soon-Shiong and NantWorks share our belief in the promise of our immunotherapy platforms. Dr. Soon-Shiong is a highly accomplished physician scientist, biotechnology entrepreneur and investor who has developed successful cancer therapies including an FDA approved immunocytokine.

我们非常高兴 Soon-Shiong 博士和 NantWorks 与我们一样，坚信我们的免疫治疗平台所蕴含的前景。Soon-Shiong 博士是一位成就卓著的医师科学家、生物技术企业家和投资者，他开发了多种成功的癌症疗法，其中包括一种获美国食品药品监督管理局（FDA）批准的免疫细胞因子。

We are honored to welcome Dr. Soon-Shiong to the company’s board of directors.'.

我们很荣幸欢迎 Soon-Shiong 博士加入公司董事会。

Dr. Soon-Shiong, is an internationally recognized physician, surgeon, scientist, and philanthropist who is the author of over 100 peer-reviewed scientific publications and over 500 patents issued worldwide. Dr. Soon-Shiong is the Executive Chairman of ImmunityBio (NASDAQ: IBRX), a company he founded in 2014.

黄馨祥博士是一位国际公认的医师、外科医生、科学家和慈善家，已发表100多篇经同行评审的科学论文，并在全球范围内获得500多项专利。黄馨祥博士是ImmunityBio公司（纳斯达克股票代码：IBRX）的执行董事长，该公司由他于2014年创立。

He also serves as Chairman of NantHealth (NASDAQ:NH), a transformational healthcare company converging biomolecular medicine and bioinformatics to simplify healthcare. He is also the Chairman and CEO of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization.

他还担任NantHealth（纳斯达克股票代码：NH）的董事长，这是一家变革性的医疗保健公司，致力于融合生物分子医学与生物信息学，以简化医疗保健体系。他同时兼任陈颂雄分子医学研究所的董事长兼首席执行官，该研究所是一家非营利性医学研究机构。

Dr. Soon-Shiong is also the Owner and Executive Chairman of the Los Angeles Times..

黄馨祥博士也是《洛杉矶时报》的所有者兼执行董事长。

Dr. Soon-Shiong has founded and led global pharmaceutical companies, including American Pharmaceutical Partners, Abraxis BioScience and ImmunityBio. At Abraxis he developed Abraxane, which became the first protein nanoparticle drug for breast, lung, and pancreatic cancers. The drug achieved blockbuster status with annual sales exceeding a billion dollars.

黄馨祥博士创立并领导了多家全球制药公司，包括美国制药伙伴公司（American Pharmaceutical Partners）、Abraxis BioScience 和 ImmunityBio。在 Abraxis 期间，他开发了白蛋白结合型紫杉醇（Abraxane），该药成为首个用于乳腺癌、肺癌和胰腺癌治疗的蛋白质纳米颗粒药物。这款药物年销售额超过十亿美元，跻身重磅炸弹药物行列。

Dr. Soon-Shiong’s contribution to the advancement of the oncology field has been honored with the Distinguished Medical Science award by the Smithsonian National Museum of American History where Abraxane is now permanently housed. He has also been honored by the Vatican with the Pontifical Key Visionary Award..

黄馨祥博士对肿瘤学领域发展的贡献荣获史密森尼美国国家历史博物馆颁发的杰出医学科学奖，该博物馆现已永久收藏Abraxane（白蛋白结合型紫杉醇）。他还获得了梵蒂冈颁发的教宗远见者奖。

Dr. Soon-Shiong received his medical degree at the University of Witwatersrand, Johannesburg, South Africa and continued his training in surgery at the University of California Los Angeles where he performed the first West Coast pancreas transplant and the world’s first encapsulated islet cell transplant.

黄馨祥博士在南非约翰内斯堡的威特沃特斯兰德大学获得医学学位，随后在加利福尼亚大学洛杉矶分校继续接受外科培训，并在那里完成了美国西海岸首例胰腺移植手术以及全球首例封装胰岛细胞移植手术。

He is a practicing surgeon and an adjunct Professor of Surgery at UCLA and a visiting Professor at the Imperial College of London..

他是一名执业外科医生，同时担任加州大学洛杉矶分校的外科兼职教授以及伦敦帝国理工学院的访问教授。

Born and raised during the apartheid era in South Africa, Dr. Soon-Shiong has lived in Los Angeles since 1980 and is a citizen of the United States.

黄馨祥博士在南非种族隔离时期出生并长大，自1980年以来一直居住在洛杉矶，是美国公民。

The securities sold in the PIPE have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws.

在PIPE中出售的证券未根据经修订的《1933年证券法》（“《证券法》”）或任何州或其他适用司法管辖区的证券法进行注册，除非根据《证券法》及适用的州或其他司法管辖区证券法完成注册或适用豁免，否则不得在美国境内发行或出售。

Concurrently with the execution of the securities purchase agreement, the Company and the investors entered into a registration rights agreement pursuant to which the Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the Private Placement Shares and shares of the Company’s common stock underlying the Pre-Funded Warrants and Common Warrants (together, the “Warrant Shares”) sold in the PIPE.

在签署证券购买协议的同时，公司与投资者签订了注册权协议，根据该协议，公司同意向美国证券交易委员会（“SEC”）提交注册声明，以注册私募配售股份以及预融资权证和普通权证所对应的公司普通股股份（统称为“权证股份”）的转售，这些股份均在PIPE交易中出售。

Any offering of the Private Placement Shares and Warrant Shares under the resale registration statement will only be made by means of a prospectus..

根据转售注册声明，任何私募配售股份和认股权证股份的发售仅能通过招股说明书进行。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Company’s securities, nor shall there be any offer, solicitation, or sale of the Company’s securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

本新闻稿不构成出售要约或购买本公司证券的要约邀请，在任何此类要约、邀请或销售行为属违法的司法管辖区，亦不得构成对本公司证券的任何要约、邀请或销售。

The private placement was conducted in accordance with applicable Nasdaq rules and was priced to satisfy the “Minimum Price” requirement (as defined in the Nasdaq rules).

本次私募发行依据适用的纳斯达克规则进行，其定价符合“最低价格”要求（定义见纳斯达克规则）。

* Aruquipa MPS et al, Liver metastasis and resistance to immunotherapy in microsatellite stable colorectal cancer. A literature review; ecancer 2024, 18:1771

* Aruquipa MPS 等，微卫星稳定型结直肠癌的肝转移及对免疫治疗的耐药性：文献综述；ecancer 2024, 18:1771

About PDS Biotechnology

关于PDS生物技术公司

PDS Biotechnology is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer. The Company’s lead development program, PDS0301 (also referred to as PDS01ADC & NHS-IL12), is an investigational tumor-targeted interleukin-12 (IL-12) immunocytokine designed to deliver IL-12 preferentially to the tumor microenvironment, with the goal of enhancing anti-tumor immune activity while limiting systemic exposure.

PDS Biotechnology 是一家处于临床阶段的生物技术公司，专注于开发针对癌症的靶向免疫疗法。公司的主要开发项目 PDS0301（也称为 PDS01ADC 和 NHS-IL12）是一种在研的肿瘤靶向白细胞介素-12（IL-12）免疫细胞因子，旨在将 IL-12 优先递送至肿瘤微环境，以在限制全身暴露的同时增强抗肿瘤免疫活性。

PDS0301 has been clinically evaluated across multiple solid tumors, including metastatic colorectal cancer and prostate cancer. The Company is focused on advancing PDS0301 in indications where its tumor-targeted mechanism may help address and overcome mechanisms of resistance to immunotherapy. PDS Biotechnology also owns the Versamune® cancer vaccine platform, including PDS0101, which has been evaluated in HPV16-positive cancers. The Company intends to pursue strategic partnerships or other externally funded opportunities for the Phase 3 development of PDS0101..

PDS0301已在包括转移性结直肠癌和前列腺癌在内的多种实体瘤中进行了临床评估。公司专注于推进PDS0301在那些其肿瘤靶向机制可能有助于解决并克服免疫治疗耐药性的适应症中的开发。PDS Biotechnology还拥有Versamune®癌症疫苗平台，其中包括已在HPV16阳性癌症中接受评估的PDS0101。公司打算为PDS0101的III期开发寻求战略合作伙伴关系或其他外部资助机会。

For more information, please visit

欲了解更多信息，请访问

www.pdsbiotech.com

www.pdsbiotech.com

Forward Looking Statements

前瞻性陈述

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters.

本通讯包含涉及PDS生物技术公司（“本公司”）及其他事项的前瞻性陈述（包括经修订的1934年美国《证券交易法》第21E条和经修订的1933年美国《证券法》第27A条所定义的前瞻性陈述）。

These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others.

这些陈述可能涉及基于公司管理层当前的信念以及管理层所作的假设和目前掌握的信息，对未来计划、趋势、事件、经营成果或财务状况等方面的目标、意图和预期。前瞻性陈述通常包括具有预测性质的陈述，其依赖于或提及未来事件或条件，并包含诸如“可能”、“将”、“应该”、“会”、“期望”、“预计”、“计划”、“很可能”、“相信”、“估计”、“预测”、“打算”、“展望”、“指引”、“前景”及其他类似表述。

Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require .

前瞻性陈述基于当前的信念和假设，这些信念和假设受风险和不确定性的影响，并不保证未来的表现。由于各种因素，实际结果可能与任何前瞻性陈述中包含的结果存在重大差异，包括但不限于：公司保护其知识产权的能力；公司预期的资本需求，包括公司预期的现金跑道以及公司对其未来股权融资计划的当前预期；公司依赖额外融资来为其运营提供资金并完成其产品候选者的开发和商业化，以及筹集此类额外资本可能会限制公司运营或要求。

®

®

HPV), PDS0103 (Versamune

HPV）、PDS0103（Versamune

®

®

MUC1) and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0301, PDS0101 (Versamune

MUC1）及其他基于Versamune®的候选产品；此类试验的未来成功；公司研发计划及合作（包括任何涉及PDS0301、PDS0101（Versamune

®

®

HPV), PDS0103 (Versamune

HPV），PDS0103（Versamune

®

®

MUC1) and other Versamune

MUC1）和其他 Versamune

®

®

based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s or its partners’ ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; the risk that the Milestone Closing may not be completed in a timely manner or at all; the failure to realize the anticipated benefits of the PIPE and the other transactions described in this press release; compliance with the rules and regulations of Nasdaq; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control.

基于产品的候选药物，以及公司对此类项目和合作的结果与发现的解读，且该等结果是否足以支持公司候选药物的未来成功；公司或其合作伙伴正在进行的临床试验及针对公司当前候选药物计划开展的临床试验的成功率、时间安排和成本，包括关于应答率、启动时间、入组进度及试验完成情况（包括公司全额资助其已披露临床试验的能力，该假设基于公司当前预计费用无重大变化）、无效性分析、会议报告及摘要中公布的数据，以及中期或初步结果的获取（包括但不限于任何临床前结果或数据），这些结果不一定能预示公司正在进行临床试验的最终结果；公司关于其对候选药物作用机制的理解以及对临床开发项目和任何合作研究的临床前和早期临床结果解读的任何声明；公司持续经营的能力；里程碑交割未能及时完成或根本无法完成的风险；未能实现私募股权投资（PIPE）及本新闻稿所述其他交易的预期效益的风险；遵守纳斯达克规则和规范的情况；以及其他因素，包括立法、监管、政治和经济发展等非公司可控因素。

The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunctio.

上述对可能导致实际事件与预期存在差异的重要因素的回顾，不应被视为详尽无遗，并应结合...阅读。

Versamune

Versamune

®

®

is a registered trademark of PDS Biotechnology Corporation.

是 PDS Biotechnology Corporation 的注册商标。

Investor Contact:

投资者联系：

Mike Moyer

迈克·莫耶

LifeSci Advisors

LifeSci 顾问

Phone +1 (617) 308-4306

电话 +1 (617) 308-4306

Email:

电子邮件：

mmoyer@lifesciadvisors.com

mmoyer@lifesciadvisors.com

Media Contact:

媒体联系人：

Jude Gorman / Kiki Torpey

裘德·戈尔曼 / 琪琪·托皮

Collected Strategies

收集的策略

PDS-CS@collectedstrategies.com

PDS-CS@collectedstrategies.com